These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 31881333)

  • 21. Systematic discovery of gene fusions in pediatric cancer by integrating RNA-seq and WGS.
    van Belzen IAEM; Cai C; van Tuil M; Badloe S; Strengman E; Janse A; Verwiel ETP; van der Leest DFM; Kester L; Molenaar JJ; Meijerink J; Drost J; Peng WC; Kerstens HHD; Tops BBJ; Holstege FCP; Kemmeren P; Hehir-Kwa JY
    BMC Cancer; 2023 Jul; 23(1):618. PubMed ID: 37400763
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-throughput diagnostic profiling of clinically actionable gene fusions in lung cancer.
    Pfarr N; Stenzinger A; Penzel R; Warth A; Dienemann H; Schirmacher P; Weichert W; Endris V
    Genes Chromosomes Cancer; 2016 Jan; 55(1):30-44. PubMed ID: 26394895
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tissue recommendations for precision cancer therapy using next generation sequencing: a comprehensive single cancer center's experiences.
    Cho M; Ahn S; Hong M; Bang H; Van Vrancken M; Kim S; Lee J; Park SH; Park JO; Park YS; Lim HY; Kang WK; Sun JM; Lee SH; Ahn MJ; Park K; Kim DH; Lee S; Park W; Kim KM
    Oncotarget; 2017 Jun; 8(26):42478-42486. PubMed ID: 28477007
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Comprehensive Screening of Gene Copy Number Aberrations in Formalin-Fixed, Paraffin-Embedded Solid Tumors Using Molecular Inversion Probe-Based Single-Nucleotide Polymorphism Array.
    Singh RR; Mehrotra M; Chen H; Almohammedsalim AA; Sahin A; Bosamra A; Patel KP; Routbort MJ; Lu X; Ronald A; Mishra BM; Virani S; Medeiros LJ; Luthra R
    J Mol Diagn; 2016 Sep; 18(5):676-687. PubMed ID: 27392636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline-focussed analysis of tumour-only sequencing: recommendations from the ESMO Precision Medicine Working Group.
    Mandelker D; Donoghue M; Talukdar S; Bandlamudi C; Srinivasan P; Vivek M; Jezdic S; Hanson H; Snape K; Kulkarni A; Hawkes L; Douillard JY; Wallace SE; Rial-Sebbag E; Meric-Bersntam F; George A; Chubb D; Loveday C; Ladanyi M; Berger MF; Taylor BS; Turnbull C
    Ann Oncol; 2019 Aug; 30(8):1221-1231. PubMed ID: 31050713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A computational tool to detect DNA alterations tailored to formalin-fixed paraffin-embedded samples in cancer clinical sequencing.
    Kato M; Nakamura H; Nagai M; Kubo T; Elzawahry A; Totoki Y; Tanabe Y; Furukawa E; Miyamoto J; Sakamoto H; Matsumoto S; Sunami K; Arai Y; Suzuki Y; Yoshida T; Tsuchihara K; Tamura K; Yamamoto N; Ichikawa H; Kohno T; Shibata T
    Genome Med; 2018 Jun; 10(1):44. PubMed ID: 29880027
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reliable Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue Using Single Molecule Tags.
    Eijkelenboom A; Kamping EJ; Kastner-van Raaij AW; Hendriks-Cornelissen SJ; Neveling K; Kuiper RP; Hoischen A; Nelen MR; Ligtenberg MJ; Tops BB
    J Mol Diagn; 2016 Nov; 18(6):851-863. PubMed ID: 27637301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Next-Generation Sequencing Panels and Platforms for Detection and Verification of Somatic Tumor Variants for Clinical Diagnostics.
    Misyura M; Zhang T; Sukhai MA; Thomas M; Garg S; Kamel-Reid S; Stockley TL
    J Mol Diagn; 2016 Nov; 18(6):842-850. PubMed ID: 27770852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Deep whole-genome sequencing of 3 cancer cell lines on 2 sequencing platforms.
    Arora K; Shah M; Johnson M; Sanghvi R; Shelton J; Nagulapalli K; Oschwald DM; Zody MC; Germer S; Jobanputra V; Carter J; Robine N
    Sci Rep; 2019 Dec; 9(1):19123. PubMed ID: 31836783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of exome capture RNA-seq for highly degraded RNA with application to clinical cancer sequencing.
    Cieslik M; Chugh R; Wu YM; Wu M; Brennan C; Lonigro R; Su F; Wang R; Siddiqui J; Mehra R; Cao X; Lucas D; Chinnaiyan AM; Robinson D
    Genome Res; 2015 Sep; 25(9):1372-81. PubMed ID: 26253700
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CRISPR/Cas9 Technology-Based Xenograft Tumors as Candidate Reference Materials for Multiple EML4-ALK Rearrangements Testing.
    Peng R; Zhang R; Lin G; Yang X; Li Z; Zhang K; Zhang J; Li J
    J Mol Diagn; 2017 Sep; 19(5):766-775. PubMed ID: 28732214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FuSpot: a web-based tool for visual evaluation of fusion candidates.
    Killian JA; Topiwala TM; Pelletier AR; Frankhouser DE; Yan PS; Bundschuh R
    BMC Genomics; 2018 Feb; 19(1):139. PubMed ID: 29439649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. InFusion: Advancing Discovery of Fusion Genes and Chimeric Transcripts from Deep RNA-Sequencing Data.
    Okonechnikov K; Imai-Matsushima A; Paul L; Seitz A; Meyer TF; Garcia-Alcalde F
    PLoS One; 2016; 11(12):e0167417. PubMed ID: 27907167
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A method to reduce ancestry related germline false positives in tumor only somatic variant calling.
    Halperin RF; Carpten JD; Manojlovic Z; Aldrich J; Keats J; Byron S; Liang WS; Russell M; Enriquez D; Claasen A; Cherni I; Awuah B; Oppong J; Wicha MS; Newman LA; Jaigge E; Kim S; Craig DW
    BMC Med Genomics; 2017 Oct; 10(1):61. PubMed ID: 29052513
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantitative detection of ALK fusion breakpoints in plasma cell-free DNA from patients with non-small cell lung cancer using PCR-based target sequencing with a tiling primer set and two-step mapping/alignment.
    Kunimasa K; Kato K; Imamura F; Kukita Y
    PLoS One; 2019; 14(9):e0222233. PubMed ID: 31513617
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial: Molecular Analysis for Therapy Choice Clinical Trial.
    Lih CJ; Harrington RD; Sims DJ; Harper KN; Bouk CH; Datta V; Yau J; Singh RR; Routbort MJ; Luthra R; Patel KP; Mantha GS; Krishnamurthy S; Ronski K; Walther Z; Finberg KE; Canosa S; Robinson H; Raymond A; Le LP; McShane LM; Polley EC; Conley BA; Doroshow JH; Iafrate AJ; Sklar JL; Hamilton SR; Williams PM
    J Mol Diagn; 2017 Mar; 19(2):313-327. PubMed ID: 28188106
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a Targeted RNA Sequencing Assay for Kinase Fusion Detection in Solid Tumors.
    Reeser JW; Martin D; Miya J; Kautto EA; Lyon E; Zhu E; Wing MR; Smith A; Reeder M; Samorodnitsky E; Parks H; Naik KR; Gozgit J; Nowacki N; Davies KD; Varella-Garcia M; Yu L; Freud AG; Coleman J; Aisner DL; Roychowdhury S
    J Mol Diagn; 2017 Sep; 19(5):682-696. PubMed ID: 28802831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Testing NTRK testing: Wet-lab and in silico comparison of RNA-based targeted sequencing assays.
    Pfarr N; Kirchner M; Lehmann U; Leichsenring J; Merkelbach-Bruse S; Glade J; Hummel M; Stögbauer F; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Lassen U; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A
    Genes Chromosomes Cancer; 2020 Mar; 59(3):178-188. PubMed ID: 31652375
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
    Blumenthal GM; Mansfield E; Pazdur R
    JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.